(Boursier.com) – Sensorion announces that Dr Aniz Girach is joining the Board of Directors as an independent member. This appointment is effective following the meeting of the Board of Directors, which took place on January 3. Dr. Girach will replace Jean-François Morin. His appointment will bring the number of independent members of the Board of Directors to four, out of a total of nine.
Dr. Girach is currently the Medical Director of ProQR Therapeutics, in charge of the development of gene therapies targeting inherited retinal diseases. He previously held a similar position at Nightstar Therapeutics and Oxurion NV (formerly ThromboGenics). With over 22 years in the pharmaceutical industry, he has also served as Global Head of Ophthalmology at Merck, Vice President and Head of International Clinical Development at Alcon Laboratories as well as Medical Director / Global Franchise Manager. in ophthalmology at Eli Lilly.
Dr. Girach is an Honorary Professor at Willis Eye Hospital in Philadelphia, USA and is a member of three Scientific Advisory Boards (SABs) of international ophthalmic organizations. He is also a reviewer for five peer-reviewed journals, including Eye and IOVS, and has published four books and over 100 abstracts / articles in peer-reviewed journals.
© 2022 Boursier.com